Bayer Animal Health Showcases Global Commitment to Tr.

Bayer Animal Health Showcases Global Commitment to Transform
Livestock Production at IPVS

Vancouver, July 22, 2010 (ots/PRNewswire) - Bayer Animal Health today
revealed their new commitment to the livestock community at the 21st
International Pig Veterinary Society (IPVS) Congress in Vancouver,
Canada.

"This year's congress highlights the complex and rapidly changing
world pig production operates in and the need for constant innovation
from everyone involved.
At Bayer Animal Health, we recognise the
significant challenges our customers face in this dynamic
environment. That is why we are making a global commitment to
ensuring our innovation, practical ingenuity and scientific
excellence are available to as many pig producers as possible,"
commented Jim Gerardot, Bayer's Global Marketing Head of Food Animal
Products and former livestock producer.

"With the objective of transforming livestock production sitting
at the heart of our business, we will be supporting the industry by
providing full access to Bayer's global knowledge and resources at a
local level. We will be providing the scientific information,
educational opportunities, quality products, services and innovative
solutions needed to meet the challenges of the changing environment,
wherever they may be," added Jim Gerardot.

The need for continuing innovation and education was reinforced
by Dr Dermot Hayes of Iowa State University. "This year's meeting of
international experts shows us the latest developments in
international trade, competition for feed grain and the potential for
major disruption as a result of disease outbreaks. It is clear that
the future of successful swine production will depend on producers
staying abreast of the latest developments in the field, and rapidly
adjusting their production techniques if they are to remain
competitive in this globalised marketplace."

Data presented at the IPVS 2010 meeting also confirmed that one
of the significant issues facing all swine producers remains
coccidiosis. This common disease is believed to be present in the
majority of swine herds, causes significant financial losses and
remains a truly global issue.

In line with their commitment, and embracing the congress theme
of 'Sharing Ideas - Advancing Pig Health', Bayer Animal Health also
presented a wide range of data at IPVS. A key paper was given by Dr
Steven McOrist, whose team studied the impact of treatment with
Baycox 5% in an on-farm study of a herd of more than 5,000 swine in a
grower-finisher facility in Romania. According to Dr McOrist, "Our
study demonstrated the protective effects of Baycox on gut health in
treated pigs, with a significant drop in oocyst count in piglets
around weaning in the treated group (p < 0.01). There was also a
marked improvement in feed conversion in treated weaner-finisher pigs
(2.41 vs. 2.63), with weight gains consistently and significantly
better through to day 150 and evidence of a protective effect against
a late, moderate Lawsonia exposure during the study."

Dr Bent Nielsen of Bayer Animal Health reinforced the importance
of the study stating, "Coccidiosis prevention is a critical piglet
health practice. This new information further demonstrates the added
value that improving gut health can have throughout the swine
production system."

To view the full MMR release, including video interviews with
leading veterinary experts, please click here
(http://bit.ly/IPVS2010)

About Bayer HealthCare

Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's
leading, innovative companies in the healthcare and medical products
industry and is based in Leverkusen, Germany. The company combines
the global activities of the Animal Health, Bayer Schering Pharma,
Consumer Care and Medical Care divisions. Bayer HealthCare's aim is
to discover and manufacture products that will improve human and
animal health worldwide. Find more information at
http://www.bayerhealthcare.com.

With a turnover of EUR977 million (2009) Bayer HealthCare's
Animal Health Division is one of the world's leading manufacturers of
veterinary drugs. The division manufactures and markets more than 100
different veterinary drugs and care products for livestock and
companion animals.

Forward-Looking Statements

This news release contains forward-looking statements based on
current assumptions and forecasts made by Bayer Group management.
Various known and unknown risks, uncertainties and other factors
could lead to material differences between the actual future results,
financial situation, development or performance of the company and
the estimates given here. These factors include those discussed in
our annual and interim reports to the Frankfurt Stock Exchange and in
our reports filed with the U.S. Securities and Exchange Commission
(including our Form 20-F). The company assumes no liability
whatsoever to update these forward-looking statements or to confirm
them to future events or developments.

Contact:
Kathrin Statz, +49-2173-384019
Kathrin.statz@bayerhealthcare.com

ots Originaltext: Bayer HealthCare
Im Internet recherchierbar: http://www.presseportal.de

Contact:
CONTACT: Contact: Kathrin Statz,
+49-2173-384019,Kathrin.statz@bayerhealthcare.com


********* ots.e-mail feedback *********

This mail achieved through ots.e-mail following lists:

ots-Gesundheit/Medizin
ots-Finanzen
ots-Agrar

********* ots.e-mail administration *********

ots archive: http://www.presseportal.de

Change subscription: http://www.presseportal.de/otsabo.html

Request password: http://www.presseportal.de/passwort.html

Contact: abo@presseportal.de